Siplizumab (MEDI-507) is a humanized CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naÏve and bona fide regulatory T cells[1].
Siplizumab (MEDI-507; 0.00001-10 nM) 结合 FcγR 并诱导信号转导[1]。
Siplizumab (0.0001-10 μg/mL) 介导细胞耗竭并降低 T 细胞增殖[1]。
[1]. Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Tmocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553.